VTVT - vTv Therapeutics Inc Stock Price, Fair Value and News

27.88USD0.00 (0.00%)Market Closed

Market Summary

USD27.880.00

Market Closed

0.00%

VTVT Stock Price

View Fullscreen

VTVT RSI Chart

VTVT Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-110.19

Price/Sales (Trailing)

1.1K

EV/EBITDA

-85.37

Price/Free Cashflow

-106.91

VTVT Price/Sales (Trailing)

VTVT Profitability

EBT Margin

-1293.90%

Return on Equity

-8.09%

Return on Assets

-38.05%

Free Cashflow Yield

-0.94%

VTVT Fundamentals

VTVT Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

194.7%

Rev. Growth (Qtr)

49.33%

VTVT Earnings

Earnings (TTM)

-20.6M

Earnings Growth (Yr)

-8.14%

Earnings Growth (Qtr)

-39.88%

Breaking Down VTVT Revenue

Last 7 days

7.3%

Last 30 days

15.5%

Last 90 days

189.5%

Trailing 12 Months

2898.5%

How does VTVT drawdown profile look like?

VTVT Financial Health

Current Ratio

6.04

VTVT Investor Care

Diluted EPS (TTM)

-9.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	5.0M	5.0M	2.0M	2.0M
2021	5.8M	5.2M	4.6M	4.0M
2020	0	0	0	6.4M
2019	11.3M	10.6M	7.3M	2.8M
2018	2.3M	4.8M	8.1M	12.4M
2017	288.0K	119.0K	96.0K	291.0K
2016	845.0K	917.0K	822.0K	634.0K
2015	1.3M	1.0M	776.5K	519.0K
2014	1.1M	1.3M	1.4M	1.5M
2013	0	0	0	976.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of vTv Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	baker bros. advisors lp	back to issuer	-	-	-57,657	-
Feb 27, 2024	akkaraju srinivas	acquired	2,654,080	11.81	224,732	-
Nov 29, 2022	fry john a	bought	33,772	0.8347	40,461	-
Nov 28, 2022	fry john a	bought	16,969	0.8262	20,539	-
Dec 20, 2021	perelman ronald o	sold	-100,050	1.15	-87,000	-
Feb 26, 2021	nelson rich s.	bought	28,600	2.86	10,000	-
Feb 26, 2021	nelson rich s.	bought	143,000	2.86	50,000	-
Feb 26, 2021	kozlov hersh	bought	27,400	2.74	10,000	-
Dec 17, 2020	perelman ronald o	bought	1,000,000	1.6	625,000	-
Dec 10, 2020	perelman ronald o	bought	1,000,000	1.6	625,000	-

Which funds bought or sold VTVT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	10,105	19,765	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	7,500	1,777	1,789	-%
May 15, 2024	Samsara BioCapital, LLC	added	405	4,395,420	4,865,630	0.75%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-50.00	284	12,589	-%
May 15, 2024	BAKER BROS. ADVISORS LP	new	-	2,289,800	2,289,800	0.03%
May 15, 2024	Royal Bank of Canada	reduced	-82.31	-4,000	2,000	-%
May 13, 2024	FMR LLC	new	-	259	259	-%
May 13, 2024	UBS Group AG	new	-	34,283	34,283	-%
May 10, 2024	VANGUARD GROUP INC	added	4.42	307,381	577,850	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	reduced	-3.33	336	682	-%

Are Funds Buying or Selling VTVT?

Are funds buying VTVT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VTVT

No. of Funds

Unveiling vTv Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 22, 2024	macandrews & forbes inc.	50.3%	1,535,685	SC 13D/A
Mar 05, 2024	samsara biocapital, l.p.	10.4%	265,620	SC 13D
Mar 05, 2024	baker bros. advisors lp	4.99%	122,664	SC 13D
Aug 23, 2022	medpace investors, llc	5.16%	5,397,529	SC 13G
Jun 10, 2022	g42 investments ai holdings rsc ltd.	13.4%	10,386,274	SC 13D
Jun 01, 2022	macandrews & forbes inc.	60.1%	61,427,396	SC 13D/A
Nov 12, 2021	macandrews & forbes inc.	67.0%	61,514,396	SC 13D/A
Sep 17, 2021	macandrews & forbes inc.	72.3%	61,514,396	SC 13D/A
Dec 17, 2020	macandrews & forbes inc.	79.3%	61,514,396	SC 13D/A
Dec 10, 2020	macandrews & forbes inc.	79.3%	61,514,396	SC 13D/A

Recent SEC filings of vTv Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	EFFECT	EFFECT
Apr 29, 2024	424B2	Prospectus Filed
Apr 29, 2024	424B2	Prospectus Filed
Apr 25, 2024	DEF 14A	DEF 14A
Apr 10, 2024	S-3	S-3
Mar 26, 2024	8-K	Current Report
Mar 22, 2024	SC 13D/A	13D - Major Acquisition
Mar 14, 2024	3	Insider Trading

vTv Therapeutics Inc News

Latest updates

vTv Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	49.3%	1,000,000	669,667	339,333	9,000	-	9,000	2,000,000	9,000	3,000,000	9,000	987,000	497,000	7,000	8,000	1,828,000	921,000	4,522,000	3,375,000	2,473,000	2,064,000	233,000
Operating Expenses	40.8%	6,627,000	4,707,000	7,427,000	6,352,000	5,689,000	4,036,000	8,481,000	11,118,000	4,603,000	4,679,000	5,267,000	4,569,000	6,395,000	5,433,000	6,620,000	5,208,000	4,873,000	4,856,000	11,331,000	-	-
S&GA Expenses	-100.0%	-	2,569,000	3,485,000	2,388,000	2,634,000	1,831,000	5,348,000	5,716,000	2,221,000	2,242,000	2,164,000	2,035,000	1,989,000	1,770,000	2,392,000	2,386,000	2,073,000	2,158,000	2,737,000	2,255,000	-
R&D Expenses	23.9%	2,649,000	2,138,000	3,942,000	3,964,000	3,055,000	2,205,000	3,133,000	5,402,000	2,382,000	2,437,000	3,103,000	2,534,000	4,406,000	3,663,000	4,228,000	2,822,000	2,800,000	2,698,000	8,594,000	-	-
EBITDA Margin	-0.6%	-12.88	-12.81	-10.56	-12.27	-13.95	-4.79	-4.15	-4.35	-1.33	-1.30	-1.85	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	7,000	-	6,000	8,000	-	1,000	6,000	6,000	-	-	67,000	283,000	404,000	514,000	626,000	743,000	822,000	870,000	855,000	852,000
Income Taxes	-	100,000	-	-	-	-	-	200,000	-	100,000	-	15,000	-	-	-	100,000	-	-	-	200,000	-	-
Earnings Before Taxes	-33.3%	-5,919,000	-4,441,000	-5,774,000	-6,090,000	-5,468,000	-4,091,000	-9,224,000	-9,483,000	-1,365,000	-841,000	-5,927,000	1,607,000	-6,882,000	-5,960,000	-5,014,000	-3,982,000	-2,328,000	-1,961,000	-9,396,000	-	-
EBT Margin	-0.6%	-12.94	-12.87	-10.62	-12.33	-14.01	-4.82	-4.17	-4.40	-1.42	-1.42	-1.99	-	-	-	-	-	-	-	-	-	-
Net Income	-39.9%	-4,865,000	-3,478,000	-4,499,000	-4,745,000	-4,261,000	-3,151,000	-7,007,000	-7,051,000	-1,087,000	-608,000	-4,241,000	1,126,000	-4,399,000	-3,608,000	-2,882,000	-2,155,000	-1,091,000	-796,000	-3,072,000	-	-
Net Income Margin	-1.8%	-10.22	-10.03	-8.25	-9.50	-10.64	-3.65	-3.14	-3.24	-1.04	-1.01	-1.38	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-151.7%	-7,335,000	-2,914,000	-5,166,000	-6,880,000	-8,827,000	706,000	-1,021,000	-6,417,000	-3,594,000	-3,998,000	-5,299,000	-2,212,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	391.8%	54.00	11.00	15.00	22.00	29.00	33.00	36.00	37.00	20.00	25.00	31.00	22.00	17.00	15.00	7.00	11.00	7.00	9.00	9.00	9.00	11.00
Current Assets	405.5%	54.00	11.00	10.00	14.00	21.00	27.00	29.00	31.00	14.00	16.00	22.00	11.00	9.00	7.00	4.00	7.00	4.00	3.00	4.00	4.00	5.00
Cash Equivalents	453.2%	52.00	9.00	8.00	13.00	19.00	12.00	15.00	18.00	12.00	13.00	20.00	11.00	8.00	6.00	2.00	6.00	3.00	4.00	5.00	4.00	7.00
Net PPE	-18.8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-4.6%	28.00	30.00	29.00	29.00	28.00	27.00	28.00	30.00	14.00	10.00	8.00	9.00	10.00	11.00	13.00	17.00	17.00	18.00	19.00	22.00	23.00
Current Liabilities	-16.0%	9.00	11.00	10.00	9.00	9.00	8.00	7.00	10.00	13.00	8.00	6.00	5.00	5.00	6.00	8.00	11.00	12.00	13.00	14.00	17.00	17.00
Shareholder's Equity	-	-	-	255	254	254	254	253	244	239	238	237	224	218	209	201	199	190	184	176	167	162
Retained Earnings	-1.8%	-286	-281	-281	-280	-274	-265	-267	-253	-247	-248	-259	-273	-274	-290	-253	-268	-252	-233	-223	-217	-220
Additional Paid-In Capital	19.7%	307	256	255	254	254	255	253	244	239	238	237	224	218	209	201	199	190	184	176	167	162
Shares Outstanding	-	-	-	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	-	-	-	-	-	-	-
Float	-	-	-	-	23.00	-	-	-	23.00	-	-	-	69.00	-	-	-	30.00	-	-	-	15.00	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-151.7%	-7,335	-2,914	-4,834	-6,167	-5,166	-6,880	-8,827	706	-1,021	-6,417	-3,594	-3,998	-5,299	-2,212	-5,434	-4,794	-5,560	-5,876	-6,195	-5,497	-5,450
Share Based Compensation	-45.4%	220	403	433	399	343	291	338	167	476	994	474	452	436	272	171	186	380	423	413	401	281
Cashflow From Investing	-100.0%	-	4,404	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-68.00	-	-	-
Cashflow From Financing	17881.6%	50,144	-282	473	-	11,806	3,667	6,303	5,040	-256	266	12,325	6,384	8,001	6,132	869	8,280	4,189	5,285	6,859	2,000	8,726

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VTVT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - Unaudited - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Revenue

$ 1,000

$ 0

Operating expenses:

Research and development

2,649

3,942

General and administrative

3,978

3,485

Total operating expenses

6,627

7,427

Operating loss

(5,627)

(7,427)

Interest income

100

Loss before income taxes and noncontrolling interest

(5,919)

(5,774)

Income tax provision

100

Net loss before noncontrolling interest

(6,019)

(5,774)

Less: net loss attributable to noncontrolling interest

(1,154)

(1,275)

Net loss attributable to vTv Therapeutics Inc.

(4,865)

(4,499)

Net loss attributable to vTv Therapeutics Inc. common shareholders

(4,865)

(4,499)

Nonrelated Party

Operating expenses:

Other income, net

1,791

Related Party

Operating expenses:

Other income, net

$ (371)

$ (238)

Class A Common Stock

Operating expenses:

Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share)

^[1]

$ (1.17)

$ (2.16)

Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share)

^[1]

$ (1.17)

$ (2.16)

Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)

^[1]

4,141,492

2,084,973

Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)

^[1]

4,141,492

2,084,973

[1]	(*) Adjusted retroactively for reverse stock split

VTVT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 52,255	$ 9,446
Accounts receivable	981	102
Prepaid expenses and other current assets	571	1,044
Current deposits	65	65
Total current assets	53,872	10,657
Property and equipment, net	95	117
Operating lease right-of-use assets	216	244
Total assets	54,183	11,018
Current liabilities:
Accounts payable and accrued expenses	8,731	10,242
Current portion of operating lease liabilities	173	169
Current portion of contract liabilities	17	17
Current portion of notes payable	0	191
Total current liabilities	8,921	10,619
Contract liabilities, net of current portion	18,669	18,669
Operating lease liabilities, net of current portion	125	169
Warrant liability, related party	481	110
Total liabilities	28,196	29,567
Commitments and contingencies
Redeemable noncontrolling interest	0	6,131
Stockholders’ equity (deficit):
Additional paid-in capital	306,887	256,335
Accumulated deficit	(286,121)	(281,042)
Total stockholders’ equity (deficit) attributable to vTv Therapeutics Inc.	20,796	(24,680)
Noncontrolling interest	5,191	0
Total stockholders’ equity (deficit)	25,987	(24,680)
Total liabilities, redeemable noncontrolling interest and stockholders’ equity (deficit)	54,183	11,018
Class A Common Stock
Stockholders’ equity (deficit):
Common stock value	24	21
Class B Common Stock
Stockholders’ equity (deficit):
Common stock value	$ 6	$ 6

About vTv Therapeutics Inc

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

CEO	Mr. Paul J. Sekhri M.Sc., MSc
WEBSITE	https://vtvtherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	13

vTv Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for vTv Therapeutics Inc? What does VTVT stand for in stocks?

VTVT is the stock ticker symbol of vTv Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of vTv Therapeutics Inc (VTVT)?

As of Fri May 17 2024, market cap of vTv Therapeutics Inc is 2.27 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VTVT stock?

You can check VTVT's fair value in chart for subscribers.

What is the fair value of VTVT stock?

You can check VTVT's fair value in chart for subscribers. The fair value of vTv Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of vTv Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VTVT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is vTv Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether VTVT is over valued or under valued. Whether vTv Therapeutics Inc is cheap or expensive depends on the assumptions which impact vTv Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VTVT.

What is vTv Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, VTVT's PE ratio (Price to Earnings) is -110.19 and Price to Sales (PS) ratio is 1.05 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VTVT PE ratio will change depending on the future growth rate expectations of investors.